Focus On Novel Immunotherapies in Multiple Myeloma: Key Takeaways From the Latest Conferences

processing....

Posted: 12/22/2021

This educational activity is intended for an international audience of hematologists/oncologists outside of the United States.

The goal of this activity is to provide learners with a snapshot of the key new immunotherapy data presented at important hematology conferences.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Key new data on immunotherapies in relapsed/refractory (R/R) multiple myeloma (MM)

Page 1 of 3

Activity Evaluation Questionnaire

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Ajai Chari, MD

Editor

Sanneke Koekkoek

Focus On Novel Immunotherapies in Multiple Myeloma: Key Takeaways From the Latest Conferences